Literature DB >> 7507188

Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop.

H Yoshiyama1, H Mo, J P Moore, D D Ho.   

Abstract

The biologically cloned human immunodeficiency virus type 1 (HIV-1) RF isolate is sensitive to neutralization by the murine monoclonal antibody (MAb) G3-4 to a conformationally sensitive epitope in the V2 loop of HIV-1 gp120. To assess how variation in the V2 amino acid sequence affects neutralization by this MAb, we cultured RF in the presence of G3-4 to select neutralization escape mutants. Three such mutants resistant to G3-4 neutralization were generated from three independent experiments. Solubilized gp120 from each of these escape mutants had a reduced affinity for G3-4 and also for two other V2 MAbs that were able to bind the wild-type RF gp120. PCR sequencing of the entire gp120 of the wild-type RF virus and the escape mutants showed that amino acid substitutions had occurred only at two positions, Y177H and L179P, both in V2. Experimental introduction of the Y177H substitution into the RF V2 loop in the context of the NL4-3 molecular clone re-created the G3-4-resistant phenotype. The L179P mutant was not viable. Thus, our findings confirm that the HIV-1 V2 loop contains the conformationally sensitive neutralization epitope recognized by G3-4 and that a single amino acid substitution within this region can result in escape variants that arise from immune selection pressure.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507188      PMCID: PMC236535     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies.

Authors:  K A Kent; E Rud; T Corcoran; C Powell; C Thiriart; C Collignon; E J Stott
Journal:  AIDS Res Hum Retroviruses       Date:  1992-06       Impact factor: 2.205

2.  Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.

Authors:  P Westervelt; H E Gendelman; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

Review 3.  Generation of diversity in retroviruses.

Authors:  R A Katz; A M Skalka
Journal:  Annu Rev Genet       Date:  1990       Impact factor: 16.830

Review 4.  Neutralization of HIV-1: a paradox of humoral proportions.

Authors:  P L Nara; R R Garrity; J Goudsmit
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

5.  Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.

Authors:  D D Ho; M S Fung; Y Z Cao; X L Li; C Sun; T W Chang; N C Sun
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

6.  Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region.

Authors:  T Masuda; S Matsushita; M J Kuroda; M Kannagi; K Takatsuki; S Harada
Journal:  J Immunol       Date:  1990-11-15       Impact factor: 5.422

7.  Identification of a neutralizing domain in the external envelope glycoprotein of simian immunodeficiency virus.

Authors:  S Benichou; R Legrand; N Nakagawa; T Faure; F Traincard; G Vogt; D Dormont; P Tiollais; M P Kieny; P Madaule
Journal:  AIDS Res Hum Retroviruses       Date:  1992-06       Impact factor: 2.205

8.  Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.

Authors:  M S Fung; C R Sun; W L Gordon; R S Liou; T W Chang; W N Sun; E S Daar; D D Ho
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

9.  Complex intrapatient sequence variation in the V1 and V2 hypervariable regions of the HIV-1 gp 120 envelope sequence.

Authors:  L Pedroza Martins; N Chenciner; S Wain-Hobson
Journal:  Virology       Date:  1992-12       Impact factor: 3.616

10.  Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.

Authors:  P L Nara; L Smit; N Dunlop; W Hatch; M Merges; D Waters; J Kelliher; R C Gallo; P J Fischinger; J Goudsmit
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

View more
  15 in total

1.  Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.

Authors:  Ralph Pantophlet; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

2.  Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.

Authors:  J P Moore; F E McCutchan; S W Poon; J Mascola; J Liu; Y Cao; D D Ho
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

3.  Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.

Authors:  Justin R Bailey; Kara G Lassen; Hung-Chih Yang; Thomas C Quinn; Stuart C Ray; Joel N Blankson; Robert F Siliciano
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: lack of correlation with viral phenotype.

Authors:  N Wang; T Zhu; D D Ho
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

5.  Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.

Authors:  B A Watkins; S Buge; K Aldrich; A E Davis; J Robinson; M S Reitz; M Robert-Guroff
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

6.  Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.

Authors:  B Etemad-Moghadam; Y Sun; E K Nicholson; G B Karlsson; D Schenten; J Sodroski
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

7.  An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences.

Authors:  E Vicenzi; D S Dimitrov; A Engelman; T S Migone; D F Purcell; J Leonard; G Englund; M A Martin
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.

Authors:  Ruth A McCaffrey; Cheryl Saunders; Mike Hensel; Leonidas Stamatatos
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120.

Authors:  P B Fischer; G B Karlsson; T D Butters; R A Dwek; F M Platt
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure.

Authors:  P B Fischer; G B Karlsson; R A Dwek; F M Platt
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.